Management of bone metastasis in prostate cancer.

Abstract

Progression of bone metastases is the primary cause of death in prostate cancer, and skeletal-related events (SREs), including pathologic fractures, spinal cord compression, radiation, or surgery to bone can impair patients' quality of life. Over the past decade, the development of cytotoxic agents, androgen-receptor-axis-targeted therapies (ARATs), and radioligand therapies has prolonged overall survival of prostate cancer patients with bone metastases and reduced the risk of SREs. The use of bone-modifying agents has also contributed to the reduced risk of SREs. Initial use of a cytotoxic agent, docetaxel, or an ARAT agent with androgen deprivation therapy (ADT) is the current approach to metastatic castration-sensitive prostate cancer. However, there is no consensus on the optimal medication for upfront use in combination with ADT, or on specific patient selection. Recently, next-generation imaging modalities, such as whole-body magnetic resonance imaging and prostate-specific membrane antigen-positron emission tomography have been utilized to detect bone metastases at an early stage. In addition, metastasis-directed therapy, such as stereotactic body radiation therapy, has been attempted. In the future, patients with bone metastatic prostate cancer will be divided into subgroups and their treatment options will be tailored to their specific characteristics.

• Authors: Kazuo Nishimura
• Journal: Journal of bone and mineral metabolism (J Bone Miner Metab) Vol. 41 Issue 3 Pg. 317-326 (May 2023) ISSN: 1435-5604 [Electronic] Japan
• PMID: 37162606 (Publication Type: Journal Article, Review)
• Copyright: © 2023. The Japanese Society Bone and Mineral Research.

Chemical References

• Androgen Antagonists
• Androgens

Topics

• Male
• Humans
• Prostatic Neoplasms (drug therapy)
• Androgen Antagonists (therapeutic use)
• Androgens
• Magnetic Resonance Imaging
• Quality of Life
• Whole Body Imaging
• Bone Neoplasms (drug therapy, secondary)